For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
This report studies the 10-Deacetylbaccatin III market. 10-Deacetylbaccatin III, also known as 10-DAB or 10-DAB III, is a closely related natural organic compounds isolated from dried needles and small branches of the European yew tree (Taxus baccata).10-Deacetylbaccatin III is a precursor to the anti-cancer drug docetaxel (Taxotere). pacitaxel (taxol); cabazitaxel. 10-10-deacetylbaccatin III was found to selectively inhibit the growth of L. DONOVANI intracellular amastigotes within J774 murine macrophages in vitro at nanomolar concentrations with an IC(50) value of 70 nM.
Scope of the Report:
As new companies enter the market for finished paclitaxel, bulk demand will increase as competition forces down prices, the study notes, adding that, with the drug becoming more affordable, physicians are expected to prescribe it more freely. However, while demand may be rising, paclitaxel is derived from a natural resource, and its long-term availability is in question.
Yew trees are slow-growing, and the extraction process requires numerous trees to supply an adequate amount, it says. The possible scarcity of the product is spurring sales, especially to the research sector where large stocks are necessary for proper experimentation. However, the report notes that enterprising companies have found ways to circumvent this issue and increase supply.
With advances in technology, new and better ways of extracting paclitaxel have evolved, with plant cell culture techniques and genetic engineering also emerging as fruitful methods of enhancing production says F&S. These methods have resulted in ample and continuous supplies, which is expected to boost the quantities of bulk paclitaxel, and subsequently augment the revenues generated by finished products, the report adds.
The worldwide market for 10-Deacetylbaccatin III is expected to grow at a CAGR of roughly 4.3% over the next five years, will reach 74 million US$ in 2024, from 58 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the 10-Deacetylbaccatin III in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- SM Herbals
- Alchem International
- Indena
- South Pharmaceutical
- HAOXUAN
- Yuannan Hande
- Sai Phytoceuticals
- Sarv Biolabs Pvt
- Aphios
- Hainan Yew Pharmaceutical
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- =95%
- =98.0%
- Others
Market Segment by Applications, can be divided into
- Production of Docetaxel
- Production of Paclitaxel
- Others
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe 10-Deacetylbaccatin III product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of 10-Deacetylbaccatin III, with price, sales, revenue and global market share of 10-Deacetylbaccatin III in 2017 and 2018.
Chapter 3, the 10-Deacetylbaccatin III competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the 10-Deacetylbaccatin III breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, 10-Deacetylbaccatin III market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe 10-Deacetylbaccatin III sales channel, distributors, customers, research findings and conclusion, appendix and data source.